Shots:
FDA approval was based on the P-III (TEMPO) program, which evaluated Juvmo in early PD pts not taking oral levodopa (TEMPO-1 & 2) & as an adjunct to oral levodopa vs PBO + levodopa in PD pts with motor fluctuations (TEMPO-3)
At Wk. 26 in TEMPO-1, Juvmo showed MDS-UPDRS Part II scores of −1.6…
